Does BoomRx mark up drug pricing?

If a vendor says its pricing is competitive, ask how you can confirm it. With BoomRx, request an itemized breakdown that separates the partner pharmacy drug cost from any platform, facilitation, shipping beyond the $30 flat fee, or processing charge. If the rate comes back as a single blended per-vial number in the dashboard, the competitive-pricing claim is unfalsifiable from your side — not necessarily false, but unverifiable. Also ask whether the rate is the partner pharmacy's cost passed straight through, or a network-negotiated rate that includes BoomRx's economics in a way that simply is not labeled as markup.

The point is not to assume bad faith. Network-scale buying across 503A, 503B, and brand partners can genuinely lower drug cost. The point is that competitive pricing is a structure question: a model where you can see drug cost and fee separately lets you confirm the claim, while a portal-gated dashboard number asks you to believe it.

Fizy Health is built around that structure. It shows resolved per-vial 503A drug cost on each catalog and cart line before checkout, and discloses a single facilitation fee separately at payment. Drug cost passes through and the fee is named, so you are not asked to trust a competitive-pricing claim — you can read the components and add them up yourself before you order.

For a clinic, that turns the pass-through question from a marketing line into a number. You can compare visible drug cost plus disclosed fee against any BoomRx dashboard rate on the same SKU, add the $30 shipping fee per patient order, and see which actually delivers lower landed cost. Whichever model wins on your real SKUs is the right one — but only a visible structure lets you make that call before you commit.